The biotech industry on the whole was on a massive winning streak in 2012, and it has started 2013 in a similar fashion. In fact, the iShares Nasdaq Biotechnology index is already up 13% since the start of this year, and there have been a few biotech stocks, such as Keryx Biopharmaceuticals, that have more than doubled.
However, for every biotech success there are a plethora of failures. Poor clinical trial data or drug recalls are some of the things that can cause stocks to plunge virtually overnight. For investors thinking about retirement, it's best to stay away from the smaller players in this speculative and complex industry. Instead, more diversified dividend stocks like Johnson & Johnson (NYSE:JNJ) are typically much safer investments. Health care analyst Max Macaluso sheds light on this topic in the following video.
Max Macaluso, Ph.D. and Sharon Yep have no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.